Department of Biosciences and Bioengineering, D Y Patil International University , Akurdi, Pune, Maharashtra, 411044, India.
Department of Pulmonary Medicine, Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh, India.
Sci Rep. 2024 Jul 13;14(1):16164. doi: 10.1038/s41598-024-67090-x.
The present study investigated the relationship between MSH3 and MSH6 genes in lung cancer patients. Genotyping of lung cancer patients and healthy controls was performed. Odds ratio values were calculated and survival analysis performed. Patients with mutant genotype (TT) for MSH6 polymorphism have 1.5-fold risk for the development of lung cancer (p = 0.03). For non-smokers, the mutant-type genotype had a threefold increased risk of lung cancer (p = 0.01). Patients administered with docetaxel and carbo/cisplatin and carrying GT genotype for MSH6 polymorphism, patients reported a decrease in median survival time (4.9 vs 9.13 months). MSH3 and MSH6 polymorphisms are involved in modulating the risk towards lung cancer. MSH6 polymorphism is associated with high mortality rate for patients undergoing cisplatin and docetaxel chemotherapy.
本研究探讨了 MSH3 和 MSH6 基因与肺癌患者之间的关系。对肺癌患者和健康对照者进行了基因分型。计算了比值比并进行了生存分析。MSH6 多态性突变基因型（TT）的患者患肺癌的风险增加了 1.5 倍（p = 0.03）。对于不吸烟者，突变型基因型患肺癌的风险增加了三倍（p = 0.01）。接受多西紫杉醇和卡铂/顺铂治疗且 MSH6 多态性 GT 基因型的患者，中位生存时间缩短（4.9 个月比 9.13 个月）。MSH3 和 MSH6 多态性参与调节肺癌的风险。MSH6 多态性与接受顺铂和多西紫杉醇化疗的患者高死亡率相关。
